Showing 10 posts of 10 posts found.

Sobi acquires CTI BioPharma Corporation for $1.7bn

May 10, 2023
Medical Communications CTI, acquisition, sobi

Swedish Orphan Biovitrum, aka Sobi, has announced that it had entered into a ‘plan of merger’ with CTI BioPharma Corp …

FDA approves first ever therapy for ultra rare primary haemophagocytic lymphohistiocytosis

November 21, 2018
Research and Development, Sales and Marketing FDA, Novimmune, pharma, sobi

The partnership of Sobi and Novimmune has revealed that their interferon gamma (IFNγ) blocking antibody Gamifant (emapalumab-lzsg) has received approval …


AstraZeneca sells off paediatric lung infection drug to Sobi for $1.5bn

November 13, 2018
Manufacturing and Production, Sales and Marketing AstraZeneca, Synagis, espiratory syncytial virus, pharma, sobi

AstraZeneca has jettisoned another non-essential asset with the sale of Synagis (palivizumab), a preventative treatment for infections relating to respiratory …


Sobi receives expanded EU approval for Kineret

April 11, 2018
Research and Development, Sales and Marketing Kineret, anti-inflammatory, biotech, drugs, pharma, pharmaceutical, sobi

Joining its current indication as a treatment for rheumatoid arthritis and cryopyrin-associated periodic syndromes, Sobi’s Kineret has been given approval …


Sobi says US FDA approves higher dose of Orfadin to treat rare genetic disorder

June 15, 2016
Research and Development, Sales and Marketing US FDA, genetic disorder, regulation, sobi

Swedish Orphan Biovitrum AB (Sobi) on Wednesday said the US Food and Drug Administration (FDA) has approved a higher strength …


Sobi, Biogen’s haemophilia B therapy gets European approval

May 13, 2016
Medical Communications, Research and Development, Sales and Marketing Biogen, haemophilia B, orphan designation, regulation, sobi

Sobi (STO: SOBI) and Biogen (Nasdaq: BIIB) on Friday said the European Commission has approved their drug to treat haemophilia B. The …


Sobi profits rise as it rolls out haemophilia drug in Europe

April 28, 2016
Financial, Q1, earnings, results, revenue, sobi

Swedish Orphan Biovitrum (Sobi) (STO: SOBI) nearly doubled its first-quarter profit driven by immediate reimbursements from Germany. The company reported …


Sobi launches new haemophilia treatment in UK

January 19, 2016
Manufacturing and Production, Sales and Marketing elocta, haemophilia a, sobi

Swedish Orphan Biovitrum Ltd (Sobi) has launched its haemophilia A treatment Elocta (efmoroctocog alfa) in the UK, following its EU …

Biogen image

Sobi and Biogen’s haemophilia A treatment EU-approved

November 27, 2015
Sales and Marketing Biogen, elocta, haemophilia a, sobi

Elocta, the haemophilia A treatment developed by the Swedish Orphan Biovitrum (Sobi) and Biogen, has received European Commission approval as …

Biogen image

EMA review for Biogen Idec’s haemophilia A therapy

November 4, 2014
Sales and Marketing Biogen, elocta, eloctate, haemophilia a, idec, sobi

The EMA is set to review Biogen Idec and Sobi’s haemophilia A therapy Elocta after validating the drug’s marketing authorisation …

Latest content